Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ITCINYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeITCIIntra-Cellular Therapies$131.87$131.87$66.26▼$131.98$14.05B0.691.52 million shsN/AJNJJohnson & Johnson$152.58+0.1%$153.66$140.68▼$169.99$366.71B0.427.99 million shs9.00 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceITCIIntra-Cellular Therapies0.00%0.00%0.00%0.00%+92.54%JNJJohnson & Johnson+0.09%+0.83%-1.55%-0.43%+4.39%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationITCIIntra-Cellular Therapies0.9036 of 5 stars1.10.00.04.50.01.70.6JNJJohnson & Johnson4.9556 of 5 stars3.35.04.23.93.01.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceITCIIntra-Cellular Therapies 2.17Hold$109.70-16.81% DownsideJNJJohnson & Johnson 2.55Moderate Buy$170.8812.00% UpsideCurrent Analyst Ratings BreakdownLatest JNJ and ITCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.005/13/2025JNJJohnson & JohnsonLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2025JNJJohnson & JohnsonLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$169.00 ➝ $153.004/24/2025JNJJohnson & JohnsonBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.004/16/2025JNJJohnson & JohnsonSanford C. BernsteinSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform4/16/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.004/16/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.004/14/2025JNJJohnson & JohnsonRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.004/10/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.004/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44JNJJohnson & Johnson$88.82B4.13$13.13 per share11.62$29.69 per share5.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/AJNJJohnson & Johnson$14.07B$8.9916.9713.782.3124.42%33.46%13.30%7/16/2025 (Estimated)Latest JNJ and ITCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/16/2025Q2 2025JNJJohnson & Johnson$2.65N/AN/AN/A$22.85 billionN/A4/15/2025Q1 2025JNJJohnson & Johnson$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/AJNJJohnson & Johnson$5.203.41%N/A57.84%64 YearsLatest JNJ and ITCI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/15/2025JNJJohnson & Johnsonquarterly$1.303.37%5/27/20255/27/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioITCIIntra-Cellular TherapiesN/A7.667.51JNJJohnson & Johnson0.491.261.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipITCIIntra-Cellular Therapies92.33%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipITCIIntra-Cellular Therapies2.60%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableJNJ and ITCI HeadlinesRecent News About These CompaniesAvidian Wealth Enterprises LLC Acquires 1,698 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comStonebridge Financial Group LLC Purchases 3,860 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comKBC Group NV Sells 511,852 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Sovran Advisors LLC1 hour ago | marketbeat.comCohen Investment Advisors LLC Buys 222,560 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Acquired by Joel Isaacson & Co. LLC1 hour ago | marketbeat.comTBH Global Asset Management LLC Sells 1,861 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comK.J. Harrison & Partners Inc Reduces Stock Holdings in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Colonial River Investments LLC1 hour ago | marketbeat.comLittle House Capital LLC Buys 10,007 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comSumitomo Mitsui Trust Group Inc. Increases Stake in Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comJ. L. Bainbridge & Co. Inc. Sells 2,104 Shares of Johnson & Johnson (NYSE:JNJ)1 hour ago | marketbeat.comJohnson & Johnson: Patience Will Be RewardedJune 30 at 11:18 AM | seekingalpha.comJohnson & Johnson (NYSE:JNJ) Stock Position Raised by Confluence Wealth Services Inc.June 30 at 5:00 AM | marketbeat.comVillere ST Denis J & Co. LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)June 30 at 4:59 AM | marketbeat.comJohnson & Johnson (NYSE:JNJ) Shares Sold by Sunbelt Securities Inc.June 30 at 4:48 AM | marketbeat.comAllspring Global Investments Holdings LLC Sells 106,904 Shares of Johnson & Johnson (NYSE:JNJ)June 30 at 4:47 AM | marketbeat.comHighland Capital Management LLC Sells 21,481 Shares of Johnson & Johnson (NYSE:JNJ)June 30 at 4:27 AM | marketbeat.comMcdaniel Terry & Co. Reduces Holdings in Johnson & Johnson (NYSE:JNJ)June 30 at 4:27 AM | marketbeat.com3Chopt Investment Partners LLC Boosts Stock Position in Johnson & Johnson (NYSE:JNJ)June 30 at 4:26 AM | marketbeat.comMirae Asset Global Investments Co. Ltd. Grows Holdings in Johnson & Johnson (NYSE:JNJ)June 30 at 4:26 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNJ and ITCI Company DescriptionsIntra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Johnson & Johnson NYSE:JNJ$152.58 +0.17 (+0.11%) As of 06/30/2025 03:58 PM EasternJohnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
